EC Signs Contract with Gilead to Supply Drugs against COVID-19
The European Commission (EC) has signed a € 63 million contract with the American pharmaceutical company Gilead to supply the EU with anti-coronavirus drugs named Veklury (a trademark of the antiviral drug remdesivir), the EC press service said on Wednesday.
« In recent weeks, the (European) Commission has been working hard with Gilead to reach an agreement to supply the parties with the first approved (in the EU) COVID-19 treatment. The contract was signed yesterday, less than a month after remdesivir was authorized. « That will allow receiving medicine for thousands of patients from the beginning of August, » the European Commissioner for Health Stella Kyriakides said in the EC communiqué.
She also noted that, without weakening efforts to provide the population with reliable and effective medicines, the European Commission supports the development of vaccines against the coronavirus.
Brussels reminds that remdesivir was the first in the EU to receive permission to access the European market on July 3. This permit, the European Commission explains, facilitates early access to medicine in urgent situations of the current pandemic.
Remdesivir is intended for the treatment of adult patients and adolescents over 12 years of age who have been diagnosed with pneumonia.
At the end of June, The Guardian wrote that the United States had bought up virtually all of its stocks of remdesivir for the next three months, « leaving nothing for the UK, Europe or most of the rest of the world. »